{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,4]],"date-time":"2022-04-04T00:52:46Z","timestamp":1649033566201},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2010,5,1]],"date-time":"2010-05-01T00:00:00Z","timestamp":1272672000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"published-print":{"date-parts":[[2010,5]]},"DOI":"10.1007\/s12094-010-0521-9","type":"journal-article","created":{"date-parts":[[2010,5,18]],"date-time":"2010-05-18T02:30:50Z","timestamp":1274149850000},"page":"384-386","source":"Crossref","is-referenced-by-count":1,"title":["Rituximab monotherapy in relapsed lymphocyte-predominant Hodgkin\u2019s lymphoma"],"prefix":"10.1007","volume":"12","author":[{"given":"Laura","family":"Gal\u00e1n","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio C.","family":"S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Blanca","family":"Cantos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariano","family":"Provencio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,5,19]]},"reference":[{"key":"521_CR1","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1182\/asheducation-2006.1.266","volume":"2006","author":"L. Nogov\u00e1","year":"2006","unstructured":"Nogov\u00e1 L, Rudiger T, Engert A (2006) Biology, clinical course and management of nodular lymphocyte-predominant Hodgkin lymphoma. Hematology 2006:266\u2013272","journal-title":"Hematology"},{"key":"521_CR2","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1182\/blood-2004-02-0567","volume":"104","author":"P. Feugier","year":"2004","unstructured":"Feugier P, Labouyrie E, Djeridane M et al (2004) Comparison of initial characteristics and long-term outcome of patients with lymphocytepredominant Hodgkin lymphoma and classical Hodgkin lymphoma at clinical stages IA and IIA prospectively treated by brief anthracycline-based chemotherapies plus extended high-dose irradiation. Blood 104:2675\u20132681","journal-title":"Blood"},{"key":"521_CR3","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1111\/j.1600-0609.2005.00462.x","volume":"66","author":"L. Nogov\u00e1","year":"2005","unstructured":"Nogov\u00e1 L, Reineke T, Josting A et al (2005) Lymphocyte-predominant and classical Hodgkin\u2019s lymphoma-comparison of outcomes. Eur J Haematol 66:106\u2013110","journal-title":"Eur J Haematol"},{"key":"521_CR4","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1182\/blood.V101.2.420","volume":"101","author":"U. Rehwald","year":"2003","unstructured":"Rehwald U, Schulz H, Reiser M et al (2003) Treatment of relapsed CD20+ Hodgkin lymphoma with the monoclonal antibody rituximab is effective and well tolerated: results of a phase 2 trial of the German Hodgkin Lymphoma Study Group. Blood 101:420\u2013424","journal-title":"Blood"},{"key":"521_CR5","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1182\/blood-2007-03-078725","volume":"111","author":"H. Schulz","year":"2008","unstructured":"Schulz H, Rehwald U, Morschhauser F et al (2008) Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG). Blood 111:109\u2013111","journal-title":"Blood"},{"key":"521_CR6","doi-asserted-by":"crossref","first-page":"4285","DOI":"10.1182\/blood-2002-08-2644","volume":"101","author":"B.C. Ekstrand","year":"2003","unstructured":"Ekstrand BC, Lucas JB, Horwitz SM et al (2003) Rituximab in lymphocyte-predominant Hodgkin disease: results of a phase 2 trial. Blood 101:4285\u20134289","journal-title":"Blood"},{"key":"521_CR7","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1200\/JCO.1999.17.3.776","volume":"17","author":"V. Diehl","year":"1999","unstructured":"Diehl V, Sextro M, Franklin J et al (1999) Clinical presentation, course, and prognostic factors in lymphocyte-predominant Hodgkin\u2019s disease and lymphocyte-rich classical Hodgkin\u2019s disease: report from the European Task Force on Lymphoma Project on Lymphocyte-Predominant Hodgkin\u2019s Disease. J Clin Oncol 17:776\u2013783","journal-title":"J Clin Oncol"},{"key":"521_CR8","doi-asserted-by":"crossref","first-page":"4261","DOI":"10.1200\/JCO.2002.08.674","volume":"20","author":"J.D. Hainsworth","year":"2002","unstructured":"Hainsworth JD, Litchy S, Burris HA et al (2002) Rituximab as first line and maintenance therapy for patients with indolent non-Hodgkin\u2019s lymphoma. J Clin Oncol 20:4261\u20134267","journal-title":"J Clin Oncol"},{"key":"521_CR9","doi-asserted-by":"crossref","first-page":"3295","DOI":"10.1182\/blood-2006-05-021113","volume":"108","author":"M.H. Oers van","year":"2006","unstructured":"van Oers MH, Klasa R, Marcus RE et al (2006) Rituximab maintenance improves clinical outcome of relapsed\/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. Blood 108:3295\u20133301","journal-title":"Blood"},{"key":"521_CR10","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1182\/blood.V110.11.644.644","volume":"110","author":"S.J. Horning","year":"2007","unstructured":"Horning SJ, Bartlett NL, Breslin S et al (2007) Results of a prospective phase II trial of limited and extended Rituximab treatment in nodular lymphocyte-predominant Hodgkin\u2019s disease (NLPHD) [ASH Annual Meeting Abstracts] Blood 110:644","journal-title":"Blood"},{"key":"521_CR11","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1159\/000177953","volume":"76","author":"H.A. Azim Jr","year":"2009","unstructured":"Azim HA Jr, Pruneri G, Cocorocchio E et al (2009) Rituximab in lymphocyte-predominant Hodgkin\u2019s disease. Oncology 76:26\u201329","journal-title":"Oncology"},{"key":"521_CR12","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1097\/CCO.0b013e32832f3ca3","volume":"21","author":"L.S. Maeda","year":"2009","unstructured":"Maeda LS, Advani RH (2009) The emerging role for rituximab in the treatment of nodular lymphocyte predominant Hodgkin lymphoma. Curr Opin Oncol 21:397\u2013400","journal-title":"Curr Opin Oncol"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-010-0521-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12094-010-0521-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-010-0521-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,4]],"date-time":"2020-06-04T19:44:47Z","timestamp":1591299887000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12094-010-0521-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,5]]},"references-count":12,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2010,5]]}},"alternative-id":["521"],"URL":"https:\/\/doi.org\/10.1007\/s12094-010-0521-9","relation":{},"ISSN":["1699-048X","1699-3055"],"issn-type":[{"value":"1699-048X","type":"print"},{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,5]]}}}